Bluejay Therapeutics Presents Positive Preliminary BJT-778 Data from Phase 2 Clinical … – WFXR

The data were presented in a late-breaking poster at the European Association for the Study of the Liver (EASL) Congress 2024. In the first test arm, …

Do you trust this headline?

Based on recent headline ratings, 100% of this readership currently trusts the local media, which has an average score of 84% regionally and is currently trending positivepositive.


Media Trust Score100%